Development of -Potential Pharmacodynamic and Diagnostic Markers for Anti-IFNα Monoclonal Antibody Trials in Systemic Lupus Erythematosus
To establish potential pharmacodynamic biomarkers to information dose choice in medical trials utilizing anti-interferon-alpha (IFN-α) monoclonal antibody (mAb) remedy for systemic lupus erythematosus (SLE), we used an Affymetrix human genome array platform and recognized 110 IFN-α/β-inducible transcripts considerably upregulated in entire blood (WB) of 41 SLE sufferers. The overexpression of these genes was confirmed prospectively
Read More